Interferon γ-induced protein10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: Implications for the innate immune response

Journal of Infectious Diseases

Volumn 210, Issue 12, 2014, Pages 1881-1885

  Lin, Jennifer C ^a   Habersetzer, François ^g,h,i   Rodriguez Torres, Maribel ^f   Afdhal, Nezam ^c   Lawitz, Eric J ^d   Paulson, Matthew S ^b   Zhu, Yanni ^b   Subramanian, Gangadharan Mani ^b   McHutchison, John G ^b   Sulkowski, Mark ^e   Wyles, David L ^a   Schooley, Robert T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Alamo Medical Research   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h INSERM   (France)

ⁱ UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Direct acting antiviral therapy; Hepatitis C; Innate immunity; IP 10

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 28B; LEDIPASVIR; RIBAVIRIN; TEGOBUVIR; VEDROPREVIR; ANTIVIRUS AGENT; CXCL10 PROTEIN, HUMAN;

ADULT; AGE; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; INNATE IMMUNITY; INTERLEUKIN 28B GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; VIRUS REPLICATION; AGED; BLOOD; CHEMISTRY; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; PLASMA;

ADULT; AGED; ANTIVIRAL AGENTS; CHEMOKINE CXCL10; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, INNATE; MALE; MIDDLE AGED; PLASMA;

EID: 84928939760     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu325     Document Type: Article

References (15)

1. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-45.
2. Askarieh G, Alsio A, Pugnale P, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010;51:1523-30.
3. Butera D, Marukian S, Iwamaye AE, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005;106:1175-82.
4. Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011;53:14-22.
5. Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011;6:e17232.
6. Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2007;45:262-8.
7. Diago M, Castellano G, Garcia-Samaniego J, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006;55:374-9.
8. Chattergoon MA, Levine JS, Latanich R, Osburn WO, Thomas DL, Cox AL. High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis 2011;204:1730-40.
9. Wyles D, Rodriguez-Torres M, Lawitz E, et al. All-oral combination therapy with ledipasvir, GS-9451, tegobuvir, and ribavirin in treatment-naive genotype 1 HCV. Hepatology 2014;60:56-64.
10. Reiberger T, Aberle JH, Kundi M, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008;13:969-76.
11. Roe B, Coughlan S, Hassan J, et al. Elevated serum levels of interferongamma-inducible protein-10 in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2007;196:1053-7.
12. Zeremski M, Petrovic LM, Chiriboga L, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008;48:1440-50.
13. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009;200:1774-80.
14. Chatterjee A, Guedj J, Perelson AS. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther 2012;17:1171-82.
15. Kandathil AJ, Graw F, Quinn J, et al. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in the human liver. Gastroenterology 2013;145:1401-14.